A recent trial assessed the efficacy of the tyrosine kinase inhibitor of VEGF receptor 2 (VEGFR2), apatinib, in conjunction with camrelizumab, a fully humanized PD-1 antibody, in the setting of advanced cervical cancer. The gene discussed is PDCD1; the disease is cervical carcinoma.